BYD Rolls Off Its 3 Millionth New Energy Vehicle and Debuts A New Passenger Car Brand Matrix
16.11.2022 15:18:00 EET | Business Wire | Press release
On November 16, the roll-off production line ceremony of BYD's 3 millionth new energy vehicle was held at BYD's global headquarters. It was not only a symbolic milestone for BYD but also an important achievement for the development of new energy vehicles worldwide. While it took BYD 13 years to achieve the first one million new energy vehicle landmark, just one year later, BYD accomplished the milestone from "one million to two million new energy vehicles". Now, just in 6 months, BYD reached the milestone of " from two million to three million new energy vehicles". BYD has showcased a massive "acceleration" in the new energy vehicle industry, facilitating the rapid change of global green mobility. At the ceremony, Mr. Wang Chuanfu, Chairman and President of BYD, expressed his sincere gratitude to BYD customers, media friends, industry partners, peers, and employees.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116005467/en/
The roll-off Production Ceremony (Photo: Business Wire)
At the event, Wang Chuanfu, Chairman and President of BYD, delivered the 3 millionth new energy vehicle to Wang Shuang, a soccer player who was named Asian Football Confederation (AFC) Women’s Player of the Year in 2018. “It is a great honor to be the owner of BYD's 3 millionth new energy vehicle”, said Wang Shuang, “I hope everyone can support sustainable mobility to help Cool the Earth by 1℃ and show our strength to the world.”
“Dealing with the industrial transformation and the ever-changing consumption trends in the future, BYD will continue to focus on scientific and technological innovation. In addition to that, BYD will keep on fulfilling people’s pursuit for a better life with leading technologies and diversified products”, said Wang Chuanfu.
He also stated that building on the existing “four-in-one” security system that guarantees the safety of battery’s raw materials, battery cells, battery packs, and vehicles, BYD would introduce another pioneering technology to further improve the security system. “To reassure our customers about safety, we have made it a mission that we will carry to the end”, said Wang Chuanfu.
During the event, Wang Chuanfu announced that BYD would build a high-end brand targeting the luxury market, Yangwang, with disruptive technologies and products. Its upcoming model will launch in the first quarter of 2023, bringing users unprecedented high performance.
In addition, in 2023, BYD will release a new brand grounded in highly professional and personalized identities, to meet the diversified demand of consumers. The brand will harness the co-creation with users and warmly welcome all the franchised dealerships to join BYD for its promotion.
In the future, BYD Auto will form a powerful brand matrix including BYD (Dynasty & Ocean), Denza, Yangwang, and another new brand that specializes in professional and personalized identities, covering family cars and luxury cars. With popularized and personalized design, BYD will constantly provide high-quality products that address customers' ever-rising expectations.
Furthermore, BYD will adhere to its global strategy by further developing the global market and promoting the passenger vehicle industry globally. Currently, BYD has extended its new energy vehicle footprint to over 400 cities across 70 countries and regions on 6 continents.
The roll-off of the 3 millionth NEV is not only an important milestone in BYD's history but also the vital landmark of witnessing the acceleration of global green mobility. In the future, BYD will continue to cooperate with partners from various sectors to achieve high-quality development. Under this collaboration, BYD will also persist in facilitating the progress of the global new energy vehicle industry and accelerating the transition of our mother planet to become a greener world.
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, electronic controllers, and automotive-grade semiconductors. It has witnessed in recent years significant technological advancements, including the Blade Battery, the DM-i and DM-p hybrid technology, the e-Platform 3.0, and the CTB technology. The company is the world’s first carmaker to stop the production of fossil-fueled vehicles on EV shift and has remained top of new energy passenger vehicle sales in China for 9 years in a row.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005467/en/
Contact information
Asia-Pacific: Mia Gu, mia.gu@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: Sofίa Mardones, sofia.mardones@byd.com tel: +56 9 9821 6851
Brazil: Adalberto Maluf, adalberto.maluf@byd.com tel: +19 3514 2554
Africa: Nikki Li, li.namin@byd.com tel: +86-18938862670
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
